CDH1 and breast carcinoma: However, in 2023, the NCCN reviewed their testing guidelines and decided to remain limiting the germline genetic testing on high-risk hereditary breast and ovarian cancer (HBOC) patients for BRCA1, BRCA2, CDH1, PALB2, PTEN, and TP53 genes only instead of a universal testing on all patients with breast cancer.